News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Newsfile Corp
NEWS
IN THE PRESS
Press Releases
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
April 15, 2025
·
8 min read
Press Releases
Theralase(R) Closes Non-Brokered Private Placement
April 14, 2025
·
5 min read
Press Releases
Neural Therapeutics Strengthens IP Portfolio With a Patent Application
April 14, 2025
·
7 min read
Press Releases
Marvel Biosciences Selected to Present Alzheimer’s Research at the 2025 Alzheimer’s Association International Conference
April 14, 2025
·
4 min read
Press Releases
Moss Genomics Announces Listing on the OTC Markets
April 11, 2025
·
6 min read
Press Releases
Awakn Life Sciences Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement
April 11, 2025
·
9 min read
Press Releases
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
April 10, 2025
·
7 min read
Press Releases
Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025
April 10, 2025
·
6 min read
Press Releases
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
April 10, 2025
·
8 min read
Press Releases
NervGen Provides Quarterly “At-The-Market” Equity Program Update
April 9, 2025
·
4 min read
15 Toronto St., Suite 601 Toronto ON M5C 2E3 US
Tel: 416-806-1750
Visit website
Email Us